Professor Richard Haynes
Professor of Renal Medicine and Clinical Trials
- MRC Population Health Research Unit Programme Leader: Randomised Trials in Cardiovascular and Metabolic Disease
- MSc in Global Health Science module 8 lead: Clinical Trials and Meta-Analysis
Richard Haynes did his pre-clinical medical studies in Cambridge before moving to Oxford for his clinical studies and qualified in 2000. He came to CTSU for a period of “out of programme” research in 2006 to work on the HPS2-THRIVE trial with Prof Jane Armitage. He completed his training in renal medicine in 2011 and was appointed as an honorary consultant at the Oxford Kidney Unit. Shortly after that he was appointed to the MRC Programme Leader track and he is now Programme Leader in the MRC Population Health Research Unit for the programme in Randomised Trials in Cardiovascular and Metabolic Disease.
Effects of empagliflozin on progression of chronic kidney disease: a pre-specified secondary analysis from the EMPA-KIDNEY trial
HAYNES R. et al, (2023), Lancet Diabetes and Endocrinology
Mechanisms of rosuvastatin-related acute kidney injury following cardiac surgery: the STICS trial.
Wijesurendra RS. et al, (2023), Eur Heart J
Accelerating clinical trials: time to turn words into action.
Landray MJ. et al, (2023), Lancet, 402, 165 - 168
Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
HERRINGTON W. et al, (2023), Kidney International Reports
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Horby PW. et al, (2023)